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Abstract
Background: BAG-1 is a multifunctional co-chaperone of heat shock proteins (Hsc70/Hsp70) that
is expressed in most cells. It interacts with Bcl-2 and Raf indicating that it might connect protein
folding with other signaling pathways. Evidence that BAG-1 expression is frequently altered in
human cancers, in particular in breast cancer, relative to normal cells has been put forward but the
notion that overexpression of BAG-1 contributes to poor prognosis in tumorigenesis remains
controversial.
Methods: We have evaluated the effect of BAG-1 heterozygosity in mice in a model of non-small-
cell lung tumorigenesis with histological and molecular methods. We have generated mice
heterozygous for BAG-1, carrying a BAG-1 null allele, that in addition express oncogenic,
constitutively active C-Raf kinase (SP-C C-Raf BxB) in type II pneumocytes. SP-C C-Raf BxB mice
develop multifocal adenomas early in adulthood.
Results: We show that BAG-1 heterozygosity in mice impairs C-Raf oncogene-induced lung
adenoma growth. Lung tumor initiation was reduced by half in BAG-1 heterozygous SP-C C-Raf
BxB mice compared to their littermates. Tumor area was reduced by 75% in 4 month lungs of BAG-
1 haploinsufficient mice compared to mice with two BAG-1 copies. Whereas BAG-1
heterozygosity did not affect the rate of cell proliferation or signaling through the mitogenic
cascade in adenoma cells, it increased the rate of apoptosis.
Conclusion: Reduced BAG-1 expression specifically targets tumor cells to apoptosis and impairs
tumorigenesis. Our data implicate BAG-1 as a key player in oncogenic transformation by Raf and
identify it as a potential molecular target for cancer treatment.
Background
BAG-1 is a multifunctional protein that is expressed in
most cells. Originally identified as a Bcl-2 binding protein
[1], other interaction partners of BAG-1 were described,
including the serine threonine kinase C-Raf [2]. The C-ter-
minal "BAG domain" of BAG-1 mediates the interaction
with the Hsc70 and Hsp70 heat shock proteins [3], molec-
ular chaperones that bind proteins in non-native states
assisting them to reach a functional active conformation
[4]. BAG-1 acts as a nucleotide exchange factor in this acti-
vation cycle [3]. The above findings indicated that BAG-1
might connect protein folding with other signaling path-
ways. Signaling networks promoting cell growth and pro-
liferation are frequently deregulated in cancer [5]. The
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classical mitogenic cascade transmits stimuli from growth
factor receptors via Ras, Raf, MEK and ERK to the cell
nucleus [6]. C-Raf, like A- and B-Raf kinases also act at the
outer membrane of mitochondria to augment cell survival
[7,8]. Previously we had observed the stimulation of C-
Raf kinase activity by BAG-1 in vitro [2]. Ras and B-Raf
mutations have been found in various human cancers
[9,10]. Evidence that BAG-1 expression is frequently
altered in human cancers, in particular in breast cancer,
relative to normal cells has been put forward but the
notion that overexpression of BAG-1 contributes to poor
prognosis in tumorigenesis remains controversial [11].
Methods
Animals
Mice used in these studies were generated and maintained
according to protocols approved by the animal care and
use committee at University of Würzburg. To inactivate
the BAG-1 gene, we constructed a vector where exons 1
and 2 are replaced with a neomycin resistance gene. A
phage clone with a 15-kb genomic insert from mouse
strain 129/Sv spanning all seven exons of BAG-1 was iden-
tified and characterised using standard methods. The tar-
geting construct contained 1,1-kb from the BAG-1 locus
upstream of the neomycin resistance gene of plasmid
pPNT [12] and 6-kb downstream. The upstream arm of
1,1 kb is located 5' to the start codon in the first exon of
BAG-1 and the 3' arm of 6 kb is located downstream of
exon 2. The mutation was introduced into embryonic
stem cells by homologous recombination. Positive clones
were identified by Southern blot analysis. Germline trans-
mitting chimeras were obtained and bred to C57BL/6
mice. Further details will be described elsewhere. Hetero-
zygous BAG-1 mice were genotyped by a PCR assay. The
targeted BAG-1 allele was detected with primers P1 (5'-
GAG TCT CCC GAT CCC TTT TCC), located upstream of
exon 1, and P2 (5'-GAT TCG CAG CGC ATC GCC TT),
located in the neomycin resistance gene, yielding a prod-
uct of 600 base pairs. BAG-1 heterozygous mice were
backcrossed at least three times onto C57BL/6 back-
ground before crossing with SP-C C-Raf BxB mice. Lung
tumour mice expressing oncogenic C-Raf BxB were back-
crossed at least six times onto C57BL/6 background.
Western blot
For the analysis of BAG-1 expression, lung lysates of the
indicated genotypes were separated on 12,5% polyacryla-
mide-SDS (sodium dodecyl sulphate) gel, transferred to
nitrocellulose Protran BA83 membrane (Sch-
leicher&Schüll) and probed with rabbit anti-BAG-1 (FL-
274) antibody (1:250, Santa Cruz Biotechnology).
Amounts of protein were determined by Bradford protein
assay to ensure equal protein loading for the analysis.
Blots were developed using the appropriate horseradish
peroxidase coupled secondary antibody and the ECL sys-
tem (Amersham Pharmacia Biotech). Subsequently, the
membrane was stripped and reprobed with rabbit anti-
body to glyceraldehyde 3 phosphate dehydrogense
(1:2000, ab9485, Abcam Ltd.).
Histopathology and immunohistochemistry
Animals were sacrificed and lungs were fixed under 25 cm
water pressure with 4% paraformaldehyde and embedded
in paraffin. 5 µm sections were stained with hematoxylin
and eosin and analysed. Pictures were taken using a Leica
DMLA microscope and a Hitachi HV-C20A colour cam-
era. Immunohistochemical staining to detect activated
caspase-3, phospho-ERK (extracellular signal-regulated
kinase), PCNA (proliferating cell nuclear antigen) have
been described elsewhere [13]. Apoptotic, PCNA and p-
ERK indices were determined by evaluating randomly
chosen adenomas or fields of normal lung in 3–4 sections
and determining the percentage of positive cells per 2000
cells at ×400.
Results and discussion
BAG-1 heterozygosity impairs C-Raf driven tumorigenesis
In order to assess the functional role of BAG-1 on tumor-
igenesis, we have generated a null allele of BAG-1. To inac-
tivate the BAG-1 gene, exons 1 and 2 were replaced with a
neomycin resistance gene. This strategy was chosen to dis-
rupt the expression of all known isoforms of BAG-1 which
are generated by alternate translation initiation of a single
mRNA; the start codons are present in exons 1 and 2.
Western blot analysis of liver protein extracts of BAG-1
deficient embryos showed the complete loss of all BAG-1
protein isoforms. Embryos homozygous for this allele
died at midgestation at around E13,5, but the hetero-
zygous animals (BAG-1+/-) are normal. A comprehensive
description of the BAG-1-/- phenotype is subject of another
manuscript.
Previously, we had generated a lung cancer mouse model
by targeting constitutively active C-Raf kinase (SP-C C-Raf
BxB) to the lung [14]. These mice develop multifocal ade-
nomas early in adulthood. Based on the observation, that
BAG-1 can activate C-Raf [2], we asked whether heterozy-
gosity for BAG-1 would affect C-Raf BxB driven adenoma
growth. We observed that lung tumour initiation was
reduced by half in 1, 2 and 4 months old BAG-1+/- mice
transgenic for SP-C C-Raf BxB compared to their BAG-1+/
+  littermates. Tumour area was reduced by 75% in 4
month lungs of BAG-1 haploinsufficient mice compared
to mice with two BAG-1 copies, see Figure 1. The histolog-
ical picture emphasises the difference in adenoma forma-
tion between a representative SP-C C-Raf BxB/BAG-1+/+
and SP-C C-Raf BxB/BAG-1+/- lung. The difference in the
staining intensity of the two lung sections derives mainly
from the observation that the adenoma cells have a ten-
dency to bind more intensively hematoxylin and eosinBMC Cancer 2004, 4:85 http://www.biomedcentral.com/1471-2407/4/85
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compared to normal lung cells. Thus, reduction of the
BAG-1 gene dosage impairs the oncogenic activity of C-
Raf in vivo.
Reduced BAG-1 expression in BAG-1 heterozygous lungs
Quantitative immunoblots demonstrated that the specific
BAG-1 protein concentration in the lungs of BAG-1+/-
mice was half the amount of BAG-1+/+ littermates, see Fig-
ure 2a. Moreover, immunohistochemical staining showed
that BAG-1 was expressed in adenoma cells, see Figure 2b.
There was no obvious difference in the BAG-1 immuno-
histochemistry of SP-C C-RafBxB/BAG-1+/+ and SP-C C-
RafBxB/BAG-1+/- lungs.
Tumour cells of BAG-1 heterozygous mice show increased 
apoptosis
Concerning the molecular mechanism how a reduction of
the BAG-1 protein expression in the heterozygous mice
would impair tumorigenesis, we determined the fraction
of apoptotic cells. Staining for activated caspase-3
revealed indistinguishable apoptosis in healthy regions of
the lung of 1 month old SP-C C-Raf BxB mice with either
one or two BAG-1 alleles, in line with the unaltered, nor-
mal lung structure of BAG-1+/- mice. In the adenomas,
however, we observed a significant increase of apoptotic
cells in BAG-1+/- SP-C C-Raf BxB mice compared with their
SP-C C-Raf BxB/BAG-1+/+ littermates, see Figure 3a. This
mechanism of action of BAG-1 on the regulation of cell
survival is compatible with the phenotype of embryonic
day 12,5 BAG-1 null embryos. Immunohistochemical
staining for activated caspase-3 and trypan blue staining
of dissociated cells showed hypocellularity and elevated
levels of apoptosis in the livers of BAG-1-/-  embryos
(unpublished observations).
Proliferation and p-ERK signalling are unaffected in BAG-
1 heterozygous mice
To exclude the alternative mechanism that the decreased
level of BAG-1 expression in heterozygous animals would
cause reduced cell proliferation in the adenomas, we per-
formed proliferating cellular antigen (PCNA) staining. No
significant differences were observed in the fraction of
proliferating adenoma cells between SP-C C-Raf BxB ani-
mals heterozygous or wild type for BAG-1, see Figure 3b.
Also, the percentages of adenoma cells positive for Ki-67,
another proliferation marker and Bmi-1, a chromatin-
associated protein expressed in stem cells, were not
affected by the BAG-1 heterozygosity (not shown). Fur-
thermore, staining of lung sections for phosphorylated
ERK revealed no quantitative differences in the adenomas
of SP-C C-Raf BxB animals heterozygous or wild type for
BAG-1, see Figure 3c. Thus, signalling through the
mitogenic cascade was not affected by the BAG-1 hetero-
zygosity in the adenoma cells.
BAG-1 haplo-insufficiency delays C-Raf driven adenoma  growth Figure 1
BAG-1 haplo-insufficiency delays C-Raf driven ade-
noma growth. (a) Adenoma initiation in SP-C C-Raf BxB 
mice (BAG-1+/+) and their Bag-1 haplo-insufficient littermates 
(BAG-1+/-) at 1, 2 and 4 months of age. Adenoma foci values 
represent mean ± s.e. from at least 4 mice of each genotype 
analyzed in a blinded fashion by two independent readers. (b) 
Adenoma area in the lungs of 4 months old mice. Each value 
represents mean ± s.e. from at least 4 mice of each genotype 
analyzed in a blinded fashion. (c-d) Examples of hematoxylin-
eosin stained sections of lungs from SP-C C-Raf BxB trans-
genic mice wildtype for BAG-1 in comparison to a BAG-1 
heterozygous littermate. Scale bar, 200 µm.BMC Cancer 2004, 4:85 http://www.biomedcentral.com/1471-2407/4/85
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Conclusions
Tumours often are highly dependent on signalling path-
ways promoting cell growth or survival and may become
hypersensitive to downregulation of key components
within these signalling cascades. This study identifies
BAG-1 as a protein specifically required at wild type
expression levels for the survival of tumour cells and
reveals it as potential anticancer target. Since many key
components of survival pathways are regulated by interac-
tion with (co-)chaperones [15], our finding is not without
precedent but novel insofar as we have uncovered that
reduced BAG-1 expression specifically targets tumour cells
to apoptosis and impairs tumorigenesis. Whether this
effect on adenoma cell survival requires that BAG-1 inter-
acts with C-Raf or Hsc70/Hsp70 or with both partners
requires additional studies. Questions concerning specific
roles of the different BAG-1 isoforms were not addressed
with this BAG-1 deficient mouse as both isoforms of BAG-
1, p50 and p32 are absent in protein extracts of knock-out
embryos. Another setting where BAG-1 has a physiologi-
cal role is the heart, where up-regulation of BAG-1 after
ischemia rescues cells from apoptosis [16].
A possible model combining the findings of this report
and other data indicates that BAG-1 functions as an acti-
vator of C-Raf at the outer mitochondrial membrane
where enzymatically activated C-Raf finds apoptosis-
related targets such as BAD [17], see Figure 4. We can
purify overexpressed C-Raf either in an enzymatically
inactive form in a complex with Hsp70 or in an enzymat-
ically active form in a complex with Hsp90/50 (unpub-
lished observations), and BAG-1 is proposed to regulate
this activation with ATP generated in the mitochondria.
Experiments dealing with this questions are currently
ongoing.
Therefore, the therapeutic efficacy of a standard chemo-
therapeutic agent [13] should be increased dramatically
by co-application with a BAG-1 inhibitor, since it would
target the adaptability of cancer cells to environmental
stress and overcome their genetic plasticity. One way to
reduce BAG-1 expression is through use of RNA interfer-
ence-based gene silencing, in particular as BAG-1 overex-
pression has been observed in human tumours [11].
Drugs that bind to the ATP binding site of Hsc70/Hsp70
might also be expected to be effective as they would
inhibit the interaction of BAG-1 with the ATPase domain
of heat shock proteins. Such new specific BAG-1 inhibi-
tors may be identified, aided by the known three-dimen-
sional structure of the BAG domain [18,19].
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